🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#NewsAlert: We are thrilled to announce the appointment of Nick Botwood, MBBS, as Head of Research & Development and Chief Medical Officer at Syndax. As a prominent leader and R&D visionary, Nick brings deep strategic and operational experience and a proven track record of

#MarkYourCalendars: Join members of Syndax management for a fireside chat during the Bank of America Merrill Lynch Vegas Health Care conference on Thursday, May 15 at 9:20 a.m. PT/12:20 p.m. ET. Learn how we are reimagining cancer care by accessing the link below:

#NewsAlert: We’re thrilled to announce that Syndax will be presenting clinical data showcasing revumenib and axatilimab at the European Hematology Association (EHA) Congress, including an oral presentation highlighting updated results from the frontline BEAT AML trial of

Today marks #ClinicalTrialsDay, an opportunity to pay tribute to the power of clinical trials and the many clinical research professionals who play a pivotal role in driving innovation forward. Hear from Iris Culbert, Associate Director, Clinical Operations, who describes how

During National Cancer Research Month, we reflect on the importance of #cancer research and the progress we have made through the collaboration of many stakeholders across the medical research community, especially in certain types of cancers with urgent unmet need. In this

#HappeningSoon: Join members of Syndax management for a virtual fireside chat during the TD Cowen 6th Annual Oncology Innovation Summit tomorrow, May 28 at 10:30 a.m. ET. Discover our commitment to reimagining cancer care by accessing the link below: bit.ly/3ZDtvMC A

Today marks #WorldBloodCancerDay, a day dedicated to the fight against blood cancer. #DYK that #AML currently accounts for about 1 out of 3 leukemias in adults and for about 1% of all cancers? Meet Sarah, a university administrator from St. Louis, Missouri, who graciously shared

#ICYMI: ASCO's #ASCO25 kicks off on Friday and Syndax is looking forward to joining! Visit us at Booth #27031 to learn about our passion for patients: asco.org #HemOnc #Leukemia

#DYK that #AML accounts for about 1 out of 3 leukemias in adults, and for about 1% of all cancers? Rearrangements of the KMT2A gene cause approximately 10% of acute leukemias. Learn more by visiting Booth #27031 at #ASCO25. #acutemyeloidleukemia

On #NationalCancerSurvivorsDay, we celebrate the resilience of those who have fought and continue to fight cancer, raise awareness about the challenges of cancer survivorship, and inspire hope for the future. When it comes to acute leukemia, battling cancer is only part of the

At Syndax, we are #FirstinCompassion. We aspire to reimagine cancer care not just for adults, but for pediatric patients with urgent unmet need. Learn how Syndax worked hand-in-hand with key stakeholders across the healthcare landscape to make a difference for this underserved

This month, Cancer Hope Network is launching the Hopeful Hearts: Parents Supporting Parents Peer Mentor Program. Syndax is proud to support this program, which strives to bridge a gap in the pediatric cancer community by offering emotional support, shared experiences, and practical

#MarkYourCalendars: Tomorrow, members of Syndax management will take the stage at the Jefferies Global Healthcare Conference for a fireside chat at 1:25 p.m. ET. Discover how we are reimagining cancer care by tuning in below: bit.ly/4jFpiPV A live replay will be

We’re thrilled to have participated in ASCO's #ASCO25, where we had the privilege of joining other industry innovators committed to changing the treatment paradigm for patients. Learn more about how Syndax is reimagining cancer care: syndax.com

#HappeningSoon: Join members of Syndax leadership for a fireside chat tomorrow at 2:00 p.m. ET during the Goldman Sachs 46th Annual Global Healthcare Conference. Learn more about our dedication to advancing innovative cancer therapies by joining the webcast below:

#NewsAlert: Today, we presented new data in relapsed or refractory mNPM1 and NUP98r acute leukemia from the AUGMENT-101 trial at the 30th @EHA_hematology Annual Congress Meeting. Learn more by accessing the press release below: bit.ly/3HTi8Kr #EHA2025

#NewsAlert: Today, we announced that data from the BEAT AML trial in combination with ven/aza in newly diagnosed mNPM1 and KMT2Ar #AML patients were published in the Journal of Clinical Oncology and simultaneously presented in an oral session at the 30th @EHA_hematology Annual

We enjoyed presenting at the European Hematology Association 2025 Congress, where we had the opportunity to join other industry leaders who share our determination to reimagine cancer care. Learn about our recent presentations: bit.ly/408vmcA #EHA2025 #HemOnc #Leukemia

#BreakingNews: Today, we announced that the U.S. FDA has granted Priority Review for our sNDA in relapsed or refractory mNPM1 acute myeloid leukemia (#AML). The sNDA is being reviewed under the FDA's Real-Time Oncology Review (#RTOR) program and has been assigned a PDUFA

Access helpful resources on #NationalCancerSurvivorsMonth by viewing the post from The Leukemia & Lymphoma Society below: